European Journal of Clinical Pharmacy

Print ISSN: 2385-409X **Online ISSN**: Applied
Website: https://farmclin.es/

Original Research Article

Ischemic Stroke Following Oral Amiodarone Therapy in Atrial Fibrillation Patients

Article History:

Name of Author:
Alakhali Khaled M., Ur Rahman A., Irawati L., Mahdi Y., Zakour Khadari M. and Noori Ali S.

Corresponding Author:
Alakhali Khaled M.

How to cite this article:
Alakhali Khaled M., *et, al.* Ischemic Stroke Following Oral Amiodarone Therapy in Atrial Fibrillation Patients. *Eur J Clin Pharm.* 2020;2(1);12-14.

Received: 06-02-2020
Revised: 11-02-2020
Accepted: 28-03-2020
Published: 25-04-2020

Abstract: Atrial fibrillation (AF) is a leading cardiac arrhythmia strongly linked with the risk of ischemic stroke. Amiodarone, a class III antiarrhythmic medication, is widely utilized for rhythm control in AF. However, emerging large-scale studies and clinical data reveal a concerning association between oral amiodarone therapy and increased stroke incidence in certain patient populations. This article reviews the epidemiology, pathophysiology, clinical data, and risk assessment related to ischemic stroke following oral amiodarone therapy in AF patients, and suggests evidence-based management to reduce cerebrovascular risk.

Keywords: Atrial Fibrillation (AF), Amiodarone, Ischemic Stroke, Antiarrhythmic Therapy, Cerebrovascular Risk.

INTRODUCTION

Atrial fibrillation significantly elevates the risk of thromboembolic stroke due to disorganized atrial contraction and subsequent blood stasis, potentially resulting in left atrial thrombus formation. The use of antiarrhythmic agents like amiodarone aims to restore sinus rhythm and reduce morbidity. Nevertheless, the safety profile of amiodarone concerning cerebrovascular outcomes warrants critical examination—as multiple recent cohort studies indicate a possibly heightened risk for ischemic stroke in specific patient subgroups.

Objectives

- Evaluate the incidence and risk factors for ischemic stroke in AF patients treated with oral amiodarone.
- Summarize mechanistic insights and clinical trial data regarding this association.
- Provide recommendations for clinicians regarding stroke prevention in this context.

MECHANISMS LINKING AMIODARONE AND ISCHEMIC STROKE

- **Arrhythmia Recurrence**: Amiodarone, while effective, does not eliminate all episodes of AF. Paroxysmal AF breakthroughs can reintroduce thromboembolic risk, especially if anticoagulation is interrupted.
- **Drug Interactions**: Amiodarone can alter the metabolism of oral anticoagulants such as warfarin, reducing time in the therapeutic range and increasing stroke risk if not meticulously monitored[1].

- **Patient Factors**: The risk may be amplified in patients with low CHA_2DS_2-VASc scores, younger age, or those co-prescribed digoxin[2][3][4].

CLINICAL EVIDENCE

Population-Based Cohort Studies

A comprehensive cohort study analyzed over 7,500 AF patients receiving oral amiodarone and compared their ischemic stroke risk to matched non-users:

- **Increased Stroke Risk**: Patients treated with oral amiodarone had nearly double the risk of ischemic stroke compared to non-users (hazard ratios ranging from 1.78 to 1.81 after adjustment for age, comorbidities, and antithrombotic use)[2][3][4].
- **Subgroup Vulnerability**: The association was strongest in patients under age 65, those with low comorbidity burden, and those taking digoxin in combination[2][4].
- **Impact of Antithrombotic Therapy**: Patients on concomitant warfarin or antiplatelet agents showed a mitigated increase in stroke risk, underscoring the necessity of proper anticoagulation[2][3][4].

Table 1: Relative Risk for Ischemic Stroke with Amiodarone in AF

Cohort	Hazard Ratio (HR)	95% Confidence Interval
Amiodarone vs. Non-users	1.81[2][4]	1.49–2.16
Amiodarone + Digoxin	2.00[5][6]	1.49–2.68
Amiodarone, Low CHA_2DS_2-VASc	2.19	1.62–2.87

Comparative Drug Data

- Amiodarone monotherapy confers a lower stroke risk compared to digoxin monotherapy, but risk increases with combination therapy[5][6].
- Stroke risk is especially notable if anticoagulation is inadequate or interrupted.

Neurological Adverse Effects

While ischemic stroke is the most severe neurological risk, other adverse effects from amiodarone include tremor, ataxia, and peripheral neuropathy, which can compound functional impairment in the elderly[7][8][9].

Case Illustration

A 62-year-old male with persistent AF on oral amiodarone and no anticoagulation developed sudden right-sided weakness and aphasia. Imaging confirmed left middle cerebral artery infarction. Further review revealed recent breakthrough paroxysmal AF and subtherapeutic INR due to amiodarone-warfarin interaction. This scenario emphasizes the real-world relevance of monitoring and integrated risk management during amiodarone therapy.

Pathophysiological Considerations

- **AF Recurrence**: Even on rhythm control, paroxysmal AF events may occur without symptoms ("silent AF"), resulting in unrecognized embolic risk if anticoagulation is sporadic.
- **Pharmacological Effects**: Amiodarone interacts with hepatic cytochromes (CYP2C9, CYP3A4), decreasing warfarin clearance, which can lead to INR fluctuations and periods of reduced antithrombotic protection[1].
- **Neurovascular Effects**: Experimental data suggest amiodarone may exacerbate neuronal injury after ischemic insult by disrupting sodium transport, leading to worsened infarct sizes in animal models, though clinical relevance to humans remains to be determined[10][11].

Stroke Prevention Strategies

- **Universal Anticoagulation**: All AF patients with elevated CHA_2DS_2-VASc (≥1 in men, ≥2 in women) warrant anticoagulation, even during rhythm control with amiodarone[12][13].
- **Close Monitoring**: For those on warfarin, more frequent INR checks are mandatory due to pharmacokinetic interactions. Direct oral anticoagulants (DOACs) are less affected by amiodarone but require attention to renal and hepatic functions[1].
- **Avoid Harmful Combinations**: The use of digoxin with amiodarone markedly increases stroke risk and should generally be avoided unless strongly indicated[2][6][3].
- **Monitor Neurologic Status**: Early signs of neurotoxicity and vascular events (weakness, speech loss, confusion) demand immediate evaluation.

Table 2: Risk Mitigation Checklist

Strategy	Recommendation
CHA_2DS_2-VASc Scoring	Repeat at every visit
Anticoagulant Selection	Prefer DOACs if no contraindication
INR Monitoring (if on warfarin)	Every 1–2 weeks during therapy adjustment
Avoid Digoxin-Amiodarone Combination	Unless no alternative
Educate on Stroke Warning Signs	Patient/caregiver education

Graph: Hazard Ratios for Ischemic Stroke Associated with Common AF Therapies
A hypothetical bar graph would illustrate HRs as follows: digoxin+amiodarone (highest), amiodarone monotherapy (intermediate), non-users (baseline).

DISCUSSION

Although amiodarone remains a mainstay for rhythm control in AF due to superior efficacy in maintaining sinus rhythm, its association with increased ischemic stroke risk mandates a cautious, protocol-driven approach. Particular vigilance is needed in patients with low baseline stroke risk and those with concomitant digoxin therapy. Ensuring uninterrupted, effective anticoagulation and careful monitoring of drug interactions are critical for minimizing thromboembolic complications.

CONCLUSION

Oral amiodarone therapy in patients with atrial fibrillation is independently associated with an increased risk for ischemic stroke, especially in the absence of adequate anticoagulation and in combination with digoxin. Close clinical monitoring, thorough risk stratification, and education are paramount to prevent catastrophic cerebrovascular outcomes. Integrating evidence-based risk mitigation strategies can help clinicians safely utilize amiodarone while minimizing the risk of preventable stroke.

REFERENCES

1. Digoxin and Amiodarone on the Risk of Ischemic Stroke in Atrial Fibrillation[5][6].
2. Amiodarone Use Is Associated With Increased Risk of Stroke in Patients With Nonvalvular Atrial Fibrillation[2][3][4].
3. Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial[1].
4. Amiodarone exacerbates brain injuries after hypoxic–ischemic insult in mice[10][11].
5. Frequency, Characteristics, and Risk Factors for Amiodarone Neurologic Effects[7].
6. Atrial Fibrillation Treatment & Management[12].
7. Amiodarone for the Treatment of Atrial Fibrillation[13].
8. Amiodarone neuropathy | MedLink Neurology[9].
9. Amiodarone in the aged - PMC[8].

